CrossrefInfokarte
Cost-effectiveness of sunitinib as second-line treatment for gastrointestinal stromal tumor in the People’s Republic of China [Corrigendum]
Comparative Effectiveness Research · 2018
DOI: 10.2147/cer.s151220 ↗Abstract
Kein Abstract verfügbar.
EUVIMED